Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Purchased by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. boosted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 34.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,860 shares of the company’s stock after buying an additional 12,569 shares during the period. E Fund Management Co. Ltd.’s holdings in Roivant Sciences were worth $549,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. FMR LLC boosted its position in shares of Roivant Sciences by 8.1% in the 3rd quarter. FMR LLC now owns 38,910,625 shares of the company’s stock valued at $454,476,000 after purchasing an additional 2,913,491 shares during the period. Morgan Stanley boosted its position in shares of Roivant Sciences by 48.7% in the 3rd quarter. Morgan Stanley now owns 19,311,631 shares of the company’s stock valued at $225,560,000 after purchasing an additional 6,324,915 shares during the period. Rubric Capital Management LP boosted its position in shares of Roivant Sciences by 196.9% in the 3rd quarter. Rubric Capital Management LP now owns 10,500,000 shares of the company’s stock valued at $122,640,000 after purchasing an additional 6,963,562 shares during the period. Vanguard Group Inc. boosted its position in shares of Roivant Sciences by 159.1% in the 3rd quarter. Vanguard Group Inc. now owns 5,602,566 shares of the company’s stock valued at $65,438,000 after purchasing an additional 3,440,374 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Roivant Sciences by 5.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,023,027 shares of the company’s stock valued at $22,719,000 after purchasing an additional 99,148 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Stock Performance

Shares of ROIV stock traded down $0.17 during trading on Wednesday, reaching $11.21. The company had a trading volume of 5,092,369 shares, compared to its average volume of 6,515,017. The firm’s 50 day simple moving average is $10.87 and its two-hundred day simple moving average is $10.44. The company has a debt-to-equity ratio of 0.06, a current ratio of 27.79 and a quick ratio of 27.79. Roivant Sciences Ltd. has a one year low of $8.24 and a one year high of $13.24. The company has a market capitalization of $9.03 billion, a PE ratio of 2.16 and a beta of 1.30.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Tuesday, February 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.07. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. The business had revenue of $37.14 million for the quarter, compared to the consensus estimate of $30.72 million. Sell-side analysts forecast that Roivant Sciences Ltd. will post -1.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on ROIV shares. Deutsche Bank Aktiengesellschaft raised their price objective on Roivant Sciences from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Truist Financial restated a “buy” rating and set a $23.00 price objective on shares of Roivant Sciences in a research report on Monday, March 25th. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Monday, April 22nd. Wolfe Research started coverage on Roivant Sciences in a research report on Thursday, February 15th. They set an “outperform” rating and a $17.00 price objective for the company. Finally, The Goldman Sachs Group raised their price objective on Roivant Sciences from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $16.90.

Insider Activity at Roivant Sciences

In related news, COO Eric Venker sold 96,950 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $10.92, for a total value of $1,058,694.00. Following the transaction, the chief operating officer now directly owns 532,207 shares of the company’s stock, valued at approximately $5,811,700.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.60% of the stock is owned by company insiders.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.